Seelos Therapeutics Revenue 2010-2022 | SEEL

Seelos Therapeutics revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Seelos Therapeutics Annual Revenue
(Millions of US $)
2021 $
2020 $
2019 $0
2018 $
2017 $
2016 $
2015 $5
2014 $9
2013 $3
2012 $8
2011 $4
2010 $5
2009 $3
Seelos Therapeutics Quarterly Revenue
(Millions of US $)
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30 $0
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31 $3
2015-09-30 $1
2015-06-30 $0
2015-03-31 $0
2014-12-31 $2
2014-09-30 $2
2014-06-30 $5
2014-03-31
2013-12-31 $0
2013-09-30 $0
2013-06-30 $1
2013-03-31 $1
2012-12-31 $2
2012-09-30 $5
2012-06-30 $0
2012-03-31 $1
2011-12-31 $0
2011-09-30 $1
2011-06-30 $2
2011-03-31 $2
2010-12-31 $1
2010-09-30 $1
2010-06-30 $1
2010-03-31 $1
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.061B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00